Build the ecosystem
A central collaboration platform for device makers, AI innovators, hospitals, researchers, and capital.

GCHDA is the central global platform connecting device makers, AI innovators, clinicians, regulators, and investors — accelerating commercialization for the 1 in 100 born with congenital heart disease, and the millions living with it for life.

Our mission
Despite rapid advances in structural heart interventions, AI-enabled imaging, pediatric therapeutics, and minimally invasive technology, congenital cardiovascular innovation remains under-served — fragmented across pediatric cardiology, ACHD, devices, regulatory pathways, and capital.
GCHDA exists to be the unifying ecosystem — accelerating development, commercialization, and global adoption of the technologies that will transform lifelong congenital cardiovascular care.
Read the executive briefFour strategic objectives
A central collaboration platform for device makers, AI innovators, hospitals, researchers, and capital.
Regulatory guidance, market access, clinical partnerships, procurement and reimbursement navigation.
Pediatric innovation incentives, trial modernization, harmonization and real-world evidence frameworks.
Registries, interoperability, working groups, and clinical-commercial partnerships.

Flagship programs
Cardiologists, founders, AI companies, regulators and investors — one room, once a year.
FDA, EMA and Health Canada pathways, pediatric approvals, HTA and reimbursement working groups.
KOL matchmaking, hospital pilots, commercialization mentorship and venture readiness for startups.
Shared outcomes data, real-world evidence, and AI-ready datasets for multi-center collaboration.
Founding coalition · 2026
We are recruiting founding members, advisory council partners, and anchor sponsors across industry, clinical leadership, and capital. The first cohort defines the standards.
